WO2013105997A3 - Compositions et procédés de remplacement de tissu mou améliorés - Google Patents
Compositions et procédés de remplacement de tissu mou améliorés Download PDFInfo
- Publication number
- WO2013105997A3 WO2013105997A3 PCT/US2012/025400 US2012025400W WO2013105997A3 WO 2013105997 A3 WO2013105997 A3 WO 2013105997A3 US 2012025400 W US2012025400 W US 2012025400W WO 2013105997 A3 WO2013105997 A3 WO 2013105997A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- soft tissue
- compositions
- tissue replacement
- replacement methods
- improved soft
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 210000004872 soft tissue Anatomy 0.000 title abstract 2
- 230000007547 defect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Insects & Arthropods (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
L'invention concerne des compositions et des procédés permettant de traiter un défaut de tissu mou chez un individu.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12708197.4A EP2678022A2 (fr) | 2011-02-23 | 2012-02-16 | Compositions et procédés de remplacement de tissu mou améliorés |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161445928P | 2011-02-23 | 2011-02-23 | |
US61/445,928 | 2011-02-23 | ||
US13/193,744 | 2011-07-29 | ||
US13/193,744 US8697056B2 (en) | 2010-08-19 | 2011-07-29 | Compositions and soft tissue replacement methods |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013105997A2 WO2013105997A2 (fr) | 2013-07-18 |
WO2013105997A3 true WO2013105997A3 (fr) | 2014-01-09 |
Family
ID=48782054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/025400 WO2013105997A2 (fr) | 2011-02-23 | 2012-02-16 | Compositions et procédés de remplacement de tissu mou améliorés |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2678022A2 (fr) |
WO (1) | WO2013105997A2 (fr) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060069018A1 (en) * | 2002-10-10 | 2006-03-30 | Ono Pharmaceutical Co., Ltd. | Endogenous repair factor production promoters |
US20110009960A1 (en) * | 2001-11-16 | 2011-01-13 | Allergan, Inc. | Prosthetic fabric structure |
US20110008406A1 (en) * | 2009-04-20 | 2011-01-13 | Altman Gregory H | Silk Fibroin Hydrogels and Uses Thereof |
WO2012024072A1 (fr) * | 2010-08-19 | 2012-02-23 | Allergan, Inc. | Compositions à base de tissu adipeux et d'un analogue de la pge2 et leur utilisation dans le traitement d'une affection d'un tissu mou |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4756911A (en) | 1986-04-16 | 1988-07-12 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US6110590A (en) | 1998-04-15 | 2000-08-29 | The University Of Akron | Synthetically spun silk nanofibers and a process for making the same |
TWI249520B (en) | 1998-07-15 | 2006-02-21 | Ono Pharmaceutical Co | 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient |
US20080299213A2 (en) | 1999-11-05 | 2008-12-04 | Donald Kleinsek | Augmentation and repair of spincter defects with cells including adipocytic cells |
US6673285B2 (en) | 2000-05-12 | 2004-01-06 | The Regents Of The University Of Michigan | Reverse fabrication of porous materials |
US6423252B1 (en) | 2000-06-23 | 2002-07-23 | Ethicon, Inc. | Methods of making micropatterned foams |
ATE374182T1 (de) | 2000-11-27 | 2007-10-15 | Pfizer Prod Inc | Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose |
CN101921220B (zh) | 2001-07-23 | 2013-05-22 | 小野药品工业株式会社 | 治疗与骨质损失有关的疾病的含有ep4激动剂作为活性成分的药物组合物 |
US6902932B2 (en) | 2001-11-16 | 2005-06-07 | Tissue Regeneration, Inc. | Helically organized silk fibroin fiber bundles for matrices in tissue engineering |
US20040254230A1 (en) | 2001-12-03 | 2004-12-16 | Ogidigben Miller J. | Method for treating ocular hypertension |
US7651684B2 (en) | 2001-12-07 | 2010-01-26 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in augmenting autologous fat transfer |
EP1558444B1 (fr) | 2002-06-24 | 2016-09-21 | Tufts University | Biomateriaux a base de soie et leurs methodes d'utilisation |
AU2003253690A1 (en) | 2002-06-24 | 2004-01-06 | Massachusetts Institute Of Technology | Silk biomaterials and methods of use thereof |
WO2004062697A2 (fr) | 2003-01-07 | 2004-07-29 | Tufts University | Matières de fibroïne de soie et utilisation de celles-ci |
US7855226B2 (en) | 2003-02-11 | 2010-12-21 | Allergan, Inc. | Treatment of inflammatory bowel disease |
US6875787B2 (en) | 2003-02-11 | 2005-04-05 | Allergan, Inc. | 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure |
EP3231846A1 (fr) | 2003-04-10 | 2017-10-18 | Tufts University | Solution aqueuse concentrée de fibroïne de soie et son utilisation |
WO2005032418A2 (fr) | 2003-10-01 | 2005-04-14 | University Of Washington | Nouveaux biomateriaux poreux |
DE602005011928D1 (de) | 2004-01-20 | 2009-02-05 | Allergan Inc | Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
WO2006016695A1 (fr) | 2004-08-10 | 2006-02-16 | Ono Pharmaceutical Co., Ltd. | Prévention et/ou remède pour hyperpotassémie contenant un agoniste ep4 |
JP4985400B2 (ja) | 2005-06-24 | 2012-07-25 | 大正製薬株式会社 | プロスタグランジン誘導体 |
WO2007016545A2 (fr) | 2005-08-01 | 2007-02-08 | The Regents Of The University Of Michigan | Materiaux poreux presentant des geometries de tailles multiples |
FR2896511B1 (fr) | 2006-01-26 | 2012-10-26 | Centre Nat Rech Scient | Procede de culture de cellules issues du tissu adipeux et leurs applications. |
WO2008092862A1 (fr) | 2007-01-30 | 2008-08-07 | Janssen Pharmaceutica N.V. | Dérivés bicycliques utilisés comme agonistes de ep4 |
WO2008092860A1 (fr) | 2007-01-30 | 2008-08-07 | Janssen Pharmaceutica N.V. | Dérivés bicycliques comme agonistes de ep4 |
WO2008092861A1 (fr) | 2007-01-30 | 2008-08-07 | Janssen Pharmaceutica N.V. | Dérivés bicycliques utilisés comme agonistes de ep4 |
US20090317367A1 (en) | 2007-02-21 | 2009-12-24 | Cedars-Sinai Medical Center | Methods of producing preadipocytes and increasing the proliferation of adult adipose stem/progenitor cells |
KR20100016299A (ko) | 2007-05-08 | 2010-02-12 | 고쿠리츠다이가쿠호진 하마마츠이카다이가쿠 | Ep4 아고니스트를 함유하여 이루어지는 세포 상해성 t 세포의 활성화제 |
GB0810615D0 (en) | 2008-06-10 | 2008-07-16 | Glaxo Group Ltd | Novel pharmaceutical |
-
2012
- 2012-02-16 WO PCT/US2012/025400 patent/WO2013105997A2/fr active Application Filing
- 2012-02-16 EP EP12708197.4A patent/EP2678022A2/fr not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110009960A1 (en) * | 2001-11-16 | 2011-01-13 | Allergan, Inc. | Prosthetic fabric structure |
US20060069018A1 (en) * | 2002-10-10 | 2006-03-30 | Ono Pharmaceutical Co., Ltd. | Endogenous repair factor production promoters |
US20110008406A1 (en) * | 2009-04-20 | 2011-01-13 | Altman Gregory H | Silk Fibroin Hydrogels and Uses Thereof |
WO2012024072A1 (fr) * | 2010-08-19 | 2012-02-23 | Allergan, Inc. | Compositions à base de tissu adipeux et d'un analogue de la pge2 et leur utilisation dans le traitement d'une affection d'un tissu mou |
Non-Patent Citations (1)
Title |
---|
ALTMAN A M ET AL: "Adhesion, migration and mechanics of human adipose-tissue-derived stem cells on silk fibroinchitosan matrix", ACTA BIOMATERIALIA, ELSEVIER, AMSTERDAM, NL, vol. 6, no. 4, 1 April 2010 (2010-04-01), pages 1388 - 1397, XP026921459, ISSN: 1742-7061, [retrieved on 20091025], DOI: 10.1016/J.ACTBIO.2009.10.034 * |
Also Published As
Publication number | Publication date |
---|---|
WO2013105997A2 (fr) | 2013-07-18 |
EP2678022A2 (fr) | 2014-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL260585B (en) | Preparations and methods for the treatment of diseases related to the retina of the eye | |
EP3285688A4 (fr) | Implants cornéens | |
WO2012149472A9 (fr) | Procédés, compositions et trousses pour traiter et prévenir des états neurologiques | |
EP2739237A4 (fr) | Instrument chirurgical et son procédé de commande | |
EP2757999A4 (fr) | Implant de tissu dur | |
PT2689743T (pt) | Broca para cirurgia de implantes | |
EP2771397A4 (fr) | Composition de caoutchouc chargée de silice et son procédé de fabrication | |
GB201305198D0 (en) | Kits, components and methods for tissue reconstruction | |
BR112014004192A2 (pt) | composição de tratamento de sementes, e, método de tratamento de sementes | |
HK1201213A1 (en) | Nonaqueous compositions for bone hemostasis, and methods for their use and manufacture | |
WO2013023151A3 (fr) | Compositions et méthodes de traitement de maladie cœliaque | |
LT2701637T (lt) | Stuburo implantas, jo įrankis ir būdas stuburo implantui atitraukti | |
PL2681280T3 (pl) | Biomateriał, sposób wytwarzania biomateriału i jego zastosowanie | |
EP2771398A4 (fr) | Composition de caoutchouc chargée avec de la silice et son procédé de préparation | |
EP2903537A4 (fr) | Suture pour réparation de tissu mou | |
WO2012097272A8 (fr) | Compositions d'hydrogel stable incluant des additifs | |
GB2505800B (en) | Valve body arrangement and method for manufacture thereof as well as valve having the valve body arrangement | |
WO2012149334A3 (fr) | Procédés et compositions pour préparer et utiliser des anticorps spécifiques à une conformation | |
EP3016516A4 (fr) | Greffon formé de tissus mous | |
EP2732068B8 (fr) | Procédé pour améliorer la résistance à l'usure d'instruments chirurgicaux colorés | |
WO2013038269A3 (fr) | Appareil et procédés permettant de traiter des morceaux de tiges de canne à sucre | |
WO2012112757A3 (fr) | Compositions et procédés améliorés de remplacement de tissu mou | |
EP2563120A4 (fr) | Méthodes, compositions et kits de traitement thérapeutique | |
EP3236883A4 (fr) | Prothèse implantable pour la réparation de tissus mous | |
WO2011097577A9 (fr) | Compositions et procédés pour traiter ou prévenir une dégénérescence de la rétine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12708197 Country of ref document: EP Kind code of ref document: A2 |
|
REEP | Request for entry into the european phase |
Ref document number: 2012708197 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012708197 Country of ref document: EP |